It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cellular DNA damage caused by reactive oxygen species is repaired by the base excision repair (BER) pathway which includes the DNA glycosylase MUTYH. Inherited biallelic MUTYH mutations cause predisposition to colorectal adenomas and carcinoma. However, the mechanistic progression from germline MUTYH mutations to MUTYH-Associated Polyposis (MAP) is incompletely understood. Here, we sequence normal tissue DNAs from 10 individuals with MAP. Somatic base substitution mutation rates in intestinal epithelial cells were elevated 2 to 4-fold in all individuals, except for one showing a 31-fold increase, and were also increased in other tissues. The increased mutation burdens were of multiple mutational signatures characterised by C > A changes. Different mutation rates and signatures between individuals are likely due to different MUTYH mutations or additional inherited mutations in other BER pathway genes. The elevated base substitution rate in normal cells likely accounts for the predisposition to neoplasia in MAP. Despite ubiquitously elevated mutation rates, individuals with MAP do not display overt evidence of premature ageing. Thus, accumulation of somatic mutations may not be sufficient to cause the global organismal functional decline of ageing.
Inherited mutations in MUTYH have been shown to predispose patients to colorectal cancers. Here, the authors show that MUTYH mutations lead to an increased somatic base substitution mutation rate in normal intestinal epithelial cells, which is the likely cause for the increased cancer risk.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Thomas, Laura E. 2
; Abascal, Federico 3
; Jung, Hyunchul 3 ; Harvey, Luke M. R. 3 ; West, Hannah D. 4 ; Olafsson, Sigurgeir 3 ; Lee, Bernard C. H. 5 ; Coorens, Tim H. H. 3
; Lee-Six, Henry 3
; Butlin, Laura 4
; Lander, Nicola 4 ; Truscott, Rebekah 4 ; Sanders, Mathijs A. 6 ; Lensing, Stefanie V. 3 ; Buczacki, Simon J. A. 7 ; ten Hoopen, Rogier 8
; Coleman, Nicholas 9 ; Brunton-Sim, Roxanne 10 ; Rushbrook, Simon 11 ; Saeb-Parsy, Kourosh 12
; Lalloo, Fiona 13 ; Campbell, Peter J. 3 ; Martincorena, Iñigo 3
; Sampson, Julian R. 4 ; Stratton, Michael R. 3
1 Wellcome Sanger Institute, Cancer, Ageing and Somatic Mutation (CASM), Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); University of Cambridge, Department of Paediatrics, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
2 Swansea University, Institute of Life Science, Swansea, UK (GRID:grid.4827.9) (ISNI:0000 0001 0658 8800)
3 Wellcome Sanger Institute, Cancer, Ageing and Somatic Mutation (CASM), Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382)
4 Cardiff University School of Medicine, Institute of Medical Genetics, Division of Cancer and Genetics, Cardiff, UK (GRID:grid.5600.3) (ISNI:0000 0001 0807 5670)
5 Wellcome Sanger Institute, Cancer, Ageing and Somatic Mutation (CASM), Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); The University of Hong Kong, Queen Mary Hospital, Hereditary Gastrointestinal Cancer Genetic Diagnosis Laboratory, Department of Pathology, Pokfulam, Hong Kong (GRID:grid.415550.0) (ISNI:0000 0004 1764 4144)
6 Wellcome Sanger Institute, Cancer, Ageing and Somatic Mutation (CASM), Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); Erasmus University Medical Centre, Department of Haematology, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X)
7 University of Oxford, Nuffield Department of Surgical Sciences, Medical Sciences Division, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
8 University of Cambridge, Department of Oncology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
9 University of Cambridge, Department of Pathology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK (GRID:grid.24029.3d) (ISNI:0000 0004 0383 8386)
10 Norfolk and Norwich University Hospital, Norwich, UK (GRID:grid.416391.8) (ISNI:0000 0004 0400 0120)
11 Norfolk and Norwich University Hospital, Norwich, UK (GRID:grid.416391.8) (ISNI:0000 0004 0400 0120); University of East Anglia, Norwich Medical School, Norwich, UK (GRID:grid.8273.e) (ISNI:0000 0001 1092 7967)
12 University of Cambridge, Department of Surgery, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); Cambridge Biomedical Campus, Cambridge NIHR Biomedical Research Centre, Cambridge, UK (GRID:grid.5335.0)
13 Saint Mary’s Hospital, Manchester Centre for Genomic Medicine, Manchester, UK (GRID:grid.416523.7) (ISNI:0000 0004 0641 2620)




